Kidney cancer drugs equal in prolonging survival - 21 News Now, More Local News for Youngstown, Ohio -

Kidney cancer drugs equal in prolonging survival

Updated: Aug 22, 2013 10:05 AM
© iStockphoto.com © iStockphoto.com
  • More NewsMore>>

  • Remembering Idora Park over the years

    Remembering Idora Park over the years

    Wednesday, April 23 2014 8:52 PM EDT2014-04-24 00:52:10 GMT
    This Saturday will mark the 30th anniversary of the devastating fire that led to the closing of the Idora Amusement Park. Glenn Stevens took a look back at Idora Park's history and the memories it made for generations. More >>
    This Saturday will mark the 30th anniversary of the devastating fire that led to the closing of the Idora Amusement Park. Glenn Stevens took a look back at Idora Park's history and the memories it made for generations. More >>
  • Suspect in Trumbull County jail hostage crisis facing death penalty case

    Suspect in Trumbull County jail hostage crisis facing death penalty case

    Wednesday, April 23 2014 8:40 PM EDT2014-04-24 00:40:36 GMT
    One of the three inmates identified as being involved in a hostage situation at the Trumbull County jail faces criminal charges that could bring the death penalty if convicted.Authorities say that 29-year-old David Martin of Cleveland is awaiting trial for the murder of Jeremy Cole in Warren in October, 2012.Martin was a neighbor of Cole who was shot to death at a home on Oak Circle SW. A woman was also wounded during the crime.The Trumbull County Grand Jury handed up a ten count indictment a...More >>
    One of the three inmates identified as being involved in a hostage situation at the Trumbull County jail faces criminal charges that could bring the death penalty if convicted.Authorities say that 29-year-old David Martin of Cleveland is awaiting trial for the murder of Jeremy Cole in Warren in October, 2012.Martin was a neighbor of Cole who was shot to death at a home on Oak Circle SW. A woman was also wounded during the crime.The Trumbull County Grand Jury handed up a ten count indictment a...More >>
  • UPDATED

    Three inmates named in Trumbull County jail hostage situation

    Three inmates named in Trumbull County jail hostage situation

    Officials said three inmates tackled and handcuffed a corrections officer on the third floor of the jail.  The inmates are holding the officer hostage, and throughout Wednesday afternoon a peace officer has been negotiating with them to get a safe & peaceful ending.More >>
    Officials said three inmates tackled and handcuffed a corrections officer on the third floor of the jail.  The inmates are holding the officer hostage, and throughout Wednesday afternoon a peace officer has been negotiating with them to get a safe & peaceful ending.More >>
By Steven Reinberg
HealthDay Reporter

THURSDAY, Aug. 22 (HealthDay News) -- The drug pazopanib (Votrient) works as well as sunitinib (Sutent) for treating advanced kidney cancer, but it has milder side effects, a new study finds.

Although both drugs are approved by the U.S. Food and Drug Administration as first-line treatments for kidney cancer and both boost survival, pazopanib had the edge in improving the quality of life, the researchers reported.

"Kidney cancer has long been considered one of the most difficult-to-treat cancers, and is associated with a poor prognosis when it's metastasized [or spreading]," said lead researcher Dr. Robert Motzer, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City.

Now there are drugs that attack a gene that is responsible for turning kidney cells into cancer cells, he said. "There has been tremendous progress in the treatment of this disease since 2005 with these targeted drugs," Motzer said. "The first of these drugs was sunitinib, which is considered the standard in first-line treatment for kidney cancer."

This new trial was a head-to-head comparison of sunitinib and pazopanib. The researchers found both had a similar safety profile and survival benefit, but there were milder side effects with pazopanib, Motzer said. These included less fatigue and fewer sores on the bottom of the feet, he noted.

"The data also suggest that patients on pazopanib have a better quality of life than patients on sunitinib," Motzer said. Both drugs cost about the same -- about $6,500 a month -- and are covered by Medicare and many private insurers.

"Both these drugs are good options for first-line treatment," Motzer said. "They allow for us to individualize treatment for patients. In my own practice, I have changed my preferred drug from sunitinib over to pazopanib, because most patients appear to have a better quality of life with pazopanib compared with sunitinib."

The trial was paid for by GlaxoSmithKline Pharmaceuticals, the maker of pazopanib.

Dr. Jessica Kreshover, a urologist at North Shore-LIJ's Arthur Smith Institute for Urology in Lake Success, N.Y., said that "this study shows that there is more than one option for first-line therapy for renal [kidney] cancer."

According to Motzer, 65,000 people are diagnosed with kidney cancer each year in the United States. "It's the sixth most common cancer," he said. And because it is often diagnosed late, 30 percent to 50 percent of the patients develop metastasis, he added. "It's one of the top 10 cancer killers," he noted.

The report was published in the Aug. 22 issue of the New England Journal of Medicine.

"We now have a number of treatment options for kidney cancer," said Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society. "The question then becomes how do you make a choice."

Lichtenfeld noted that not only did the study show that the drugs had similar survival benefits and that pazopanib was better at improving patients' quality of life, but also that pazopanib saved health care dollars by cutting the number of doctor visits.

"We need to look at our treatments not only in terms of whether they delay the progression of the cancer or increase overall survival, but also what is the cost to the patient and the medical care system," Lichtenfeld said.

For the study, Motzer's team randomly assigned more than 1,100 patients with advanced kidney cancer to either sunitinib or pazopanib.

The investigators found both drugs fared as well in the length of time they held the cancer at bay and extended life -- about nine months.

The real difference was seen in their side effects. Patients taking pazopanib suffered less fatigue, fewer sores on the hands and feet, and fewer bouts of a blood disease called thrombocytopenia, which can cause bleeding, than patients taking sunitinib, Motzer's group found.

Some patients taking pazopanib, however, had higher levels of an enzyme called alanine aminotransferase -- a sign of potential liver damage -- than those taking sunitinib, the researchers noted.

Most importantly, according to Motzer, patients taking pazopanib rated their quality of life better than patients taking sunitinib.

More information

For more on kidney cancer, visit the American Cancer Society.

Copyright © 2013 HealthDay. All rights reserved.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.
  • More From wfmj.comMore>>

  • Restaurant plans new statue of Joe Paterno

    Restaurant plans new statue of Joe Paterno

    Wednesday, April 23 2014 12:57 PM EDT2014-04-23 16:57:56 GMT
     (AP) - Fans of the late Penn State University football coach Joe Paterno are planning to commission a new bronze statue of him, and place it across from the school. Organizers say the statue will feature Paterno sitting on a bench reading. It's expected to cost about $300,000 and would hopefully be done in 2015 by Philadelphia sculptor Zenos Frudakis. Penn State spokeswoman Lisa Powers says the school isn't involved in the plan. But a restaurant owner in downtown State Col...More >>
     (AP) - Fans of the late Penn State University football coach Joe Paterno are planning to commission a new bronze statue of him, and place it across from the school. Organizers say the statue will feature Paterno sitting on a bench reading. It's expected to cost about $300,000 and would hopefully be done in 2015 by Philadelphia sculptor Zenos Frudakis. Penn State spokeswoman Lisa Powers says the school isn't involved in the plan. But a restaurant owner in downtown State Col...More >>
  • Woman allegedly sold heroin from hospital bed

    Woman allegedly sold heroin from hospital bed

    Wednesday, April 23 2014 11:01 AM EDT2014-04-23 15:01:45 GMT
    A woman in western Pennsylvania is accused of selling heroin from a hospital intensive care unit and a hospital room.More >>
    A woman in western Pennsylvania is accused of selling heroin from a hospital intensive care unit and a hospital room.More >>
  • Jet stowaway undetected for hours before departure

    Jet stowaway undetected for hours before departure

    Tuesday, April 22 2014 11:44 PM EDT2014-04-23 03:44:25 GMT
    Surveillance cameras at San Jose International Airport successfully captured the teenager on the tarmac, climbing up the landing gear of a jet. But in the end, the cameras failed because no one noticed the security...More >>
    A 15-year-old stowaway who survived a flight over the Pacific in a jet's wheel well spent seven hours undetected in what is supposed to be a highly secure area of San Jose International Airport before the flight...More >>
  • Hot ClicksHot ClicksMore>>

  • Can an app save the planet?

    Can an app save the planet?

    This startup's Earth Day launch has a massive goal: Cut carbon emissions globally. It has its work cut out for it.
    More >>
    This startup's Earth Day launch has a massive goal: Cut carbon emissions globally. It has its work cut out for it.
    More >>
  • 'Captain America' holds onto top box office spot

    'Captain America' holds onto top box office spot

    Monday, April 21 2014 10:47 PM EDT2014-04-22 02:47:39 GMT
    LOS ANGELES (AP) - Captain America really is unbeatable - at least at the box office"Captain America: The Winter Soldier" has been the top draw at theaters for three consecutive weeks, vanquishing would-be foes including the new thriller starring Johnny Depp.According to Monday's final box office figures, the Marvel sequel added $25.6 million in ticket sales over the weekend. "The Winter Soldier" has made more than $200 million domestically since logging the best April opening in history."Hea...More >>
    LOS ANGELES (AP) - Captain America really is unbeatable - at least at the box office"Captain America: The Winter Soldier" has been the top draw at theaters for three consecutive weeks, vanquishing would-be foes including the new thriller starring Johnny Depp.According to Monday's final box office figures, the Marvel sequel added $25.6 million in ticket sales over the weekend. "The Winter Soldier" has made more than $200 million domestically since logging the best April opening in history."Hea...More >>
  • Netflix poised to raise prices after strong 1Q

    Netflix poised to raise prices after strong 1Q

    Monday, April 21 2014 10:37 PM EDT2014-04-22 02:37:26 GMT
    SAN FRANCISCO (AP) - Netflix is preparing a sequel unlikely to be a hit with its subscribers. The Internet video service is about to raise its prices for the first time in three years to help pay for more Internet video programming such as its popular political drama "House of Cards."The increase, to take place sometime before July, will hike prices by $1 or $2 per month for new customers. The company's nearly 36 million current subscribers will continue to pay $8 per month for at least the n...More >>
    SAN FRANCISCO (AP) - Netflix is preparing a sequel unlikely to be a hit with its subscribers. The Internet video service is about to raise its prices for the first time in three years to help pay for more Internet video programming such as its popular political drama "House of Cards."The increase, to take place sometime before July, will hike prices by $1 or $2 per month for new customers. The company's nearly 36 million current subscribers will continue to pay $8 per month for at least the n...More >>
Powered by WorldNow
All content © Copyright 2000 - 2014 Worldnow and WFMJ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms